Eradication of Staphyloccus Aureus in Children with Cystic Fibrosis

exp date isn't null, but text field is

Background

“MSSA is clearly a significant pathogen in CF patients. The aim of treatment is to prevent infection with, or eradicate MSSA infection from the respiratory tract” 1

“The European CF Consensus group evaluating early intervention in CF lung disease has recommended an initial 2–4 weeks of antistaphylococcal treatment with new S.aureus infection .If this eradication approach fails, they recommend a 1–3 month course of antibiotics.” 5

Guidance

EVALUATION

  • ANNUAL AUDIT OF S. AUREUS INCIDENCE RHC CF UNIT
  • ANNUAL AUDIT OF S. AUREUS ERADICATION RHC CF UNIT

NOTE
AZITHROMYCIN- 10 DAYS TREATMENT GIVES 30 DAYS COVERAGE 2

References

1. CF Trust Antibiotic Treatment for Cystic Fibrosis 2009
2. Brompton Paediatric CF Guidelines 2017 https://www.rbht.nhs.uk/our-services/paediatrics/paediatric-cystic-fibrosis-clinics/care-children-cystic-fibrosis-2017- [Revised prophylactic Azithromycin dose 2019 for inclusion in 2020 version]
3. Scottish Paediatric Cystic Fibrosis Managed Clinical Network Prescribing Guidelines 2015
4. The Leeds Method of Management. April, 2008.
5. Goss C, Muhlebach M. Review: Staphylococcus aureus and MRSA in cystic fibrosis. Journal of Cystic Fibrosis 10 (2011) 298–306

Editorial Information

Last reviewed: 01 November 2019

Next review: 01 October 2021

Author(s): DR JANE WILKINSON; DR CHRISTINE PETERS; DR ROSIE HAGUE; MR STEVE BOWHAY

Version: 1

Approved By: Paediatric Drugs & Therapeutics Committee